Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Morley

Showing results (241-250 of 261) with videos related to

Pageof 27
Sort By:
World Journal of Gastroenterology|August 28, 2024
Hepatic angiotensin-converting enzyme 2 expression in metabolic dysfunction-associated steatotic liver disease and in patients with fatal COVID-19Angus K Jacobs, Steven D Morley, Kay Samuel, et al.
Journal of Clinical Medicine|June 28, 2023
Metabolism of Acetaminophen by Enteric Epithelial Cells Mitigates Hepatocellular Toxicity In VitroKatie Morgan, Steven D Morley, Arslan K Raja, et al.
Bioorganic & Medicinal Chemistry Letters|July 21, 2009
Design of selective Cathepsin inhibitorsPaul A Bethel, Stefan Gerhardt, Emma V Jones, et al.
The Review of Scientific Instruments|November 4, 2011
Magnifying lens for 800 MeV proton radiographyF E Merrill, E Campos, C Espinoza, et al.
Bioorganic & Medicinal Chemistry Letters|February 24, 2009
5-Aminopyrimidin-2-ylnitriles as cathepsin K inhibitorsAndrew D Morley, Peter W Kenny, Brenda Burton, et al.
Translational Oncology|August 3, 2019
DIVERSet JAG Compounds Inhibit Topoisomerase II and Are Effective Against Adult and Pediatric High-Grade GliomasAlison Howarth, Claire Simms, Nitesh Kerai, et al.
ASAIO Journal (American Society for Artificial Internal Organs : 1992)|May 26, 2001
Complications common to ventricular assist device support are rare with 90 days of DeBakey VAD support in calvesT W Fossum, D Morley, D B Olsen, et al.
Lipids in Health and Disease|August 3, 2016
Erratum to: Fibrinogen production is enhanced in an in-vitro model of non-alcoholic fatty liver disease: an isolated risk factor for cardiovascular events?Emily N W Yeung, Philipp Treskes, Sarah F Martin, et al.
Lipids in Health and Disease|August 11, 2015
Fibrinogen production is enhanced in an in-vitro model of non-alcoholic fatty liver disease: an isolated risk factor for cardiovascular events?Emily N W Yeung, Philipp Treskes, Sarah F Martin, et al.
Drug Discovery Today|August 3, 2013
Fragment-based hit identification: thinking in 3DAndrew D Morley, Angelo Pugliese, Kristian Birchall, et al.
Pageof 27

Showing results (241-250 of 261) with videos related to

Sort By:
Pageof 27
World Journal of Gastroenterology|August 28, 2024
Hepatic angiotensin-converting enzyme 2 expression in metabolic dysfunction-associated steatotic liver disease and in patients with fatal COVID-19Angus K Jacobs, Steven D Morley, Kay Samuel, et al.
Journal of Clinical Medicine|June 28, 2023
Metabolism of Acetaminophen by Enteric Epithelial Cells Mitigates Hepatocellular Toxicity In VitroKatie Morgan, Steven D Morley, Arslan K Raja, et al.
Bioorganic & Medicinal Chemistry Letters|July 21, 2009
Design of selective Cathepsin inhibitorsPaul A Bethel, Stefan Gerhardt, Emma V Jones, et al.
The Review of Scientific Instruments|November 4, 2011
Magnifying lens for 800 MeV proton radiographyF E Merrill, E Campos, C Espinoza, et al.
Bioorganic & Medicinal Chemistry Letters|February 24, 2009
5-Aminopyrimidin-2-ylnitriles as cathepsin K inhibitorsAndrew D Morley, Peter W Kenny, Brenda Burton, et al.
Translational Oncology|August 3, 2019
DIVERSet JAG Compounds Inhibit Topoisomerase II and Are Effective Against Adult and Pediatric High-Grade GliomasAlison Howarth, Claire Simms, Nitesh Kerai, et al.
ASAIO Journal (American Society for Artificial Internal Organs : 1992)|May 26, 2001
Complications common to ventricular assist device support are rare with 90 days of DeBakey VAD support in calvesT W Fossum, D Morley, D B Olsen, et al.
Lipids in Health and Disease|August 3, 2016
Erratum to: Fibrinogen production is enhanced in an in-vitro model of non-alcoholic fatty liver disease: an isolated risk factor for cardiovascular events?Emily N W Yeung, Philipp Treskes, Sarah F Martin, et al.
Lipids in Health and Disease|August 11, 2015
Fibrinogen production is enhanced in an in-vitro model of non-alcoholic fatty liver disease: an isolated risk factor for cardiovascular events?Emily N W Yeung, Philipp Treskes, Sarah F Martin, et al.
Drug Discovery Today|August 3, 2013
Fragment-based hit identification: thinking in 3DAndrew D Morley, Angelo Pugliese, Kristian Birchall, et al.
Pageof 27